Blarcamesine (Anavex 2-73; Anavex Life Sciences Corp.) is an investigational oral small molecule sigma-1 receptor agonist for treatment of early Alzheimer disease.
Publications
Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Rebyota (Fecal Microbiota, Live-jslm) for Prevention of Recurrent Clostridioides Difficile Infection
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Rebyota (fecal microbiota, live-jslm) for prevention of recurrent Clostridioides difficile infection (rCDI).
Lifileucel (Amtagvi; Iovance Biotherapeutics Inc.) for Advanced Melanoma
Lifileucel (Amtagvi; Iovance Biotherapeutics Inc.) is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.
ApiFix (ApiFix Ltd.) for Treatment of Adolescent Idiopathic Scoliosis
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the currently available design of the ApiFix (ApiFix Ltd.) minimally invasive deformity correction system for spinal curvature correction in the treatment of adolescent idiopathic scoliosis.
Kerecis Omega3 Wound (Kerecis) Fish Skin Grafts for the Management of Diabetic Foot Ulcers
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Kerecis Omega3 Wound fish skin grafts for improving healing and closure of diabetic foot ulcers (DFUs).
Marnetegragene Autotemcel (Rocket Pharmaceuticals Inc.) for Severe Leukocyte Adhesion Deficiency-I
Marnetegragene autotemcel (Rocket Pharmaceuticals Inc.) is an investigational gene therapy administered by intravenous infusion for the treatment of severe leukocyte adhesion deficiency-I.
Kerecis Omega3 Wound (Kerecis) Fish Skin Grafts for Management of Burns
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of Kerecis Omega3 Wound (Kerecis) fish skin grafts for treatment of burns.
Human Acellular Vessel (HAV; Humacyte Inc.) for Dialysis Access
Human Acellular Vessel (HAV; Humacyte Inc.) is an investigational bioengineered vascular conduit proposed to establish arteriovenous access for hemodialysis in patients with end-stage renal disease.
Resamirigene Bilparvovec (Astellas Pharma Inc.) for X-linked Myotubular Myopathy
Resamirigene bilparvovec is an investigational single-infusion gene therapy proposed for the treatment of X-linked myotubular myopathy.
Human Acellular Vessel (HAV; Humacyte Inc.) for Vascular Trauma
Human Acellular Vessel (HAV; formerly Humacyl) (Humacyte Inc.) is an off-the-shelf bioengineered vascular conduit proposed for urgent arterial repair following extremity vascular trauma when a synthetic graft is not indicated, and when autologous vein use is not feasible.